Search

Saima Aslam and colleagues at University of California, San Diego have announced Phase I/II phage vs placebo trial for recurrent E. coli UTIs in female kidney transplant recipients.

Precisio Biotix Therapeutics and the Mayo Clinic have announced their first patient dosed with ClyO staph lysin for multidrug-resistant prosthetic joint infection treatment.

PHIOGEN is seeking to explore patient experiences with recurrent UTIs and attitudes toward phage therapeutics: the study involves a brief screening questionnaire followed by a survey for qualified participants who experience ongoing UTI sym

A new first in human phase 1 randomized, double-blind trial of Intralytix's ShigActive™, a Shigella phage preparation, shows it is safe and well tolerated when orally administered.

Paul Kim (Locus Biosciences, Inc.) and colleagues published a paper on the results of the first phase of their Phase 2 ELIMINATE clinical trial, where they used a CRISPR-Cas3-enhanced phage cocktail to treat uncomplicated urinary tract infe

Armata Pharmaceuticals received a $5.25 million grant from the US Department of Defense for their AP-SA02 'diSArm' clinical trial to treat S. aureus bacteremia.

Armata Pharmaceuticals has completed enrollment of its Phase 2 Tailwind study, which will evaluate efficacy of inhaled AP-PA02 in non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection. Data anticipated in the second

IPATH is calling for labs to help find Achromobacter phages for an upcoming clinical trial for cystic fibrosis with phage therapy, inviting contributions and further information via email at ipath@health.ucsd.edu.

HYpharm GmbH and the German Center for Infection Research announced that their phage lysin HY-133 has entered phase I clinical trials. HY-133 aims to prevent nasal colonization by MRSA. The trial is conducted at the University Hospital of T

Koen Wortelboer (University of Amsterdam) and colleagues conducted a controlled clinical trial to assess efficacy and safety of sterile fecal filtrate transplantation (FFT) in individuals with metabolic syndrome. Glucose metabolism was simi

BiomX announced positive results from their Phase 1b/2a trial evaluating BX004, a P. aeruginosa phage cocktail, in cystic fibrosis patients. They saw clinical improvement in pulmonary function and reduced bacterial burden, paving the way fo

Intralytix has announced the launch of a Phase 1/2a clinical trial of its VRELysin™ phage preparation to assess safety and efficacy in healthy and VRE-colonized subjects at UPMC in Pittsburgh, Pennsylvania.

The first NIH-funded phage therapy clinical trial has successfully enrolled the first six patients in Stage 1 for safety and microbiological activity, with no serious adverse events reported, and is now moving into Stage 2a, aiming to enrol

Greg German and his team in Toronto have successfully used personalized phage therapy to cure a UTI in a patient, as covered by Canada’s CTV News. This is the first patient in their clinical trial, and constitutes Canada’s first phage thera

Jagdev Singh and colleagues published a clinical trial announcement that will involve a single-arm, open-labelled study investigating the safety and tolerability of intrabronchial and nebulized phage treatment in children with cystic fibros

Copenhagen-based SNIPR Biome, a CARB-X portfolio company, has developed SNIPR001, a cocktail of CRISPR-armed phages designed to target E. coli. A recent release by Robin Berghaus of CARB-X highlights the potential of SNIPR001 to prevent blo

Kids Research (part of Sydney Children's Hospitals Network) is hosting a webinar on May 19, 2023 at 2:00 PM AEST on phage therapy entitled "Phage Therapy in Australia: STAMPing out problematic infections". The webinar will be presented by P

BiomX Inc. announced positive results from Part 1 of the Phase 1b/2a trial evaluating their novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Adaptive Phage Therapeutics announced that the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.

The Antibacterial Resistance Leadership Group will begin a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial to examine safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized